Síguenos en:



Use of herpes zoster vaccine following an autologous hematopoietic stem cell transplant showed a vaccine efficacy of 68% with a clinically acceptable safety profile, according to study results presented at the BMT Tandem Meetings. “Immunocompromised individuals, including autologous hematopoietic stem cell transplant recipients, are at increased risk [for] herpes zoster”, Javier de la Serna, MD, PhD, hematologist at Hospital 12 de Octubre in Madrid, and colleagues wrote. “The risk is highest in the first year after transplantation, with an 8% to 30% herpes zoster incidence in autologous HSCT recipients”.

Más información